Prelude Therapeutics (PRLD) Competitors $0.92 +0.05 (+5.17%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. OGI, IPHA, GNFT, CTMX, EPRX, ENGN, PBYI, EDIT, SXTC, and TILShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Organigram Global (OGI), Innate Pharma (IPHA), GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Puma Biotechnology (PBYI), Editas Medicine (EDIT), China SXT Pharmaceuticals (SXTC), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Organigram Global Innate Pharma GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals enGene Puma Biotechnology Editas Medicine China SXT Pharmaceuticals Instil Bio Prelude Therapeutics (NASDAQ:PRLD) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Do institutionals and insiders have more ownership in PRLD or OGI? 79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 63.9% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PRLD or OGI more profitable? Organigram Global has a net margin of 2.86% compared to Prelude Therapeutics' net margin of 0.00%. Organigram Global's return on equity of -8.19% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -95.37% -72.56% Organigram Global 2.86%-8.19%-5.79% Does the media refer more to PRLD or OGI? In the previous week, Organigram Global had 15 more articles in the media than Prelude Therapeutics. MarketBeat recorded 20 mentions for Organigram Global and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.40 beat Organigram Global's score of -0.20 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Organigram Global 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, PRLD or OGI? Organigram Global has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M7.05-$127.17M-$1.64-0.53Organigram Global$117.47M1.73-$33.39M$0.0530.30 Do analysts rate PRLD or OGI? Prelude Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 358.72%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Prelude Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, PRLD or OGI? Prelude Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. SummaryOrganigram Global beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.36M$2.49B$5.72B$9.77BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-0.5321.7430.9025.26Price / Sales7.05545.13403.8188.28Price / CashN/A25.4525.2228.45Price / Book0.365.579.516.00Net Income-$127.17M$31.83M$3.26B$265.34M7 Day Performance5.44%5.08%4.48%2.84%1 Month Performance8.32%4.15%5.19%1.58%1 Year Performance-83.26%11.76%31.75%25.40% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.0424 of 5 stars$0.88+0.6%$4.00+357.1%-83.3%$49.47M$7M-0.53120Earnings ReportAnalyst ForecastOGIOrganigram Global0.6604 of 5 stars$1.64+13.5%N/A-30.9%$193.67M$117.47M0.00860News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeIPHAInnate Pharma2.2524 of 5 stars$2.06-1.9%$11.00+434.0%-3.4%$193.59M$21.77M0.00220Short Interest ↑Gap UpGNFTGENFIT2.1424 of 5 stars$3.73-1.8%$13.00+248.5%-6.6%$190.01M$76.77M0.00120Positive NewsGap UpHigh Trading VolumeCTMXCytomX Therapeutics3.9442 of 5 stars$2.31-1.7%$5.75+148.9%+59.2%$189.46M$138.10M4.13170Gap UpEPRXEupraxia Pharmaceuticals1.9523 of 5 stars$5.32+1.1%$11.00+106.8%+108.6%$189.15MN/A0.0029News CoveragePositive NewsEarnings ReportAnalyst RevisionENGNenGene3.33 of 5 stars$3.69+0.3%$23.29+531.0%-39.6%$188.07MN/A0.0031Short Interest ↓PBYIPuma Biotechnology4.2381 of 5 stars$4.85+31.4%$7.00+44.3%+112.6%$185.87M$230.50M4.95200Analyst UpgradeHigh Trading VolumeEDITEditas Medicine4.2777 of 5 stars$2.20-0.5%$4.70+113.6%-24.3%$185.01M$32.31M-0.72230Earnings ReportAnalyst ForecastGap DownSXTCChina SXT Pharmaceuticals0.4016 of 5 stars$1.59-0.3%N/A-80.3%$184.48M$1.74M0.0090Short Interest ↑TILInstil Bio3.2527 of 5 stars$28.35+1.3%$119.00+319.8%+176.7%$183.55MN/A-2.37410Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies Organigram Global Alternatives Innate Pharma Alternatives GENFIT Alternatives CytomX Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives enGene Alternatives Puma Biotechnology Alternatives Editas Medicine Alternatives China SXT Pharmaceuticals Alternatives Instil Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access